Drug Type Small molecule drug |
Synonyms Azimilide, Stedicor, 阿齐利特 + [1] |
Target |
Mechanism Potassium channel blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H30Cl3N5O3 |
InChIKeyHHPSICLSNHCSNZ-UHFFFAOYSA-N |
CAS Registry149888-94-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Azimilide Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Shock | Phase 3 | CZ | 30 Nov 2011 | |
Shock | Phase 3 | FR | 30 Nov 2011 | |
Shock | Phase 3 | IL | 30 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | - | - | |
Shock | Phase 1 | DK | 30 Nov 2011 | |
Postmyocardial infarction syndrome | Phase 1 | US | - | |
Postmyocardial infarction syndrome | Phase 1 | CA | - | - |
Shock | Preclinical | AU | 30 Nov 2011 | |
Atrial Fibrillation | Preclinical | US | - | |
Atrial Flutter | Preclinical | US | - |
Not Applicable | - | 240 | (orzqmkwxjb): OR = 0.79 (95% CI, 0.44 - 1.44) View more | Negative | 01 Mar 2017 | ||
Placebo |